| Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393] | Technology appraisal guidance | TBC |
| Fertility problems: assessment and treatment - update 1 and 2 | NICE guideline | TBC |
| Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Technology appraisal guidance | TBC |
| Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032] | Technology appraisal guidance | TBC |
| Finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514 | Technology appraisal guidance | TBC |
| Flow tDCS | Medtech innovation briefings | TBC |
| Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133] | Technology appraisal guidance | TBC |
| Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264] | Highly specialised technology | TBC |
| Fruquintinib for previously treated metastatic colorectal cancer ID6274 | Technology appraisal guidance | TBC |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Technology appraisal guidance | |
| GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain | Medical technologies guidance | TBC |
| Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312 | Technology appraisal guidance | TBC |
| Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323] | Technology appraisal guidance | |
| Glaucoma - lerdelimumab (CAT-152) [ID383] | Technology appraisal guidance | TBC |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202] | Technology appraisal guidance | |
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487 | Technology appraisal guidance | |
| Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 | Technology appraisal guidance | TBC |
| Guselkumab for treating moderately to severely active ulcerative colitis ID6237 | Technology appraisal guidance | |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627 | Technology appraisal guidance | TBC |
| Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343] | Technology appraisal guidance | TBC |
| Ibrutinib for treating relapsed or refractory follicular lymphoma [1251] | Technology appraisal guidance | TBC |
| Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483] | Technology appraisal guidance | TBC |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547] | Technology appraisal guidance | |
| Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922] | Technology appraisal guidance | TBC |
| Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373] | Technology appraisal guidance | TBC |